Siddappa Byrareddy

Dr. Siddappa Byrareddy

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Journal of Autoimmunity
Verified
Journal Article
Closed access
HUSSIN ROTHANHUSSIN ROTHAN
HUSSIN ROTHAN
SBSiddappa Byrareddy
Siddappa Byrareddy

1 December 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
KBKaranam Balasubramanyam
Karanam Balasubramanyam
RVRadhika A. Varier
Radhika A. Varier
MAMohammed Altaf
Mohammed Altaf
VSVenkatesh Swaminathan
Venkatesh Swaminathan
SBSiddappa Byrareddy
Siddappa Byrareddy
TKTapas K. Kundu
Tapas K. Kundu
Acetylation of histones and non-histone proteins is an important post-translational modification involved in the regulation of gene expression in eukaryotes and all viral DNA that integrates into the human genome (e.g. the human immunodeficiency virus). Dysfunction of histone acetyltransferases (HATs) is often associated with the manifestation of several diseases. In this respect, HATs are the new potential targets for the design of therapeutics. In this study, we report that curcumin (diferuloylmethane), a major curcumanoid in the spice turmeric, is a specific inhibitor of the p300/CREB-binding protein (CBP) HAT activity but not of p300/CBP-associated factor, in vitro and in vivo. Furthermore, curcumin could also inhibit the p300-mediated acetylation of p53 in vivo. It specifically represses the p300/CBP HAT activity-dependent transcriptional activation from chromatin but not a DNA template. It is significant that curcumin could inhibit the acetylation of HIV-Tat protein in vitro by p300 as well as proliferation of the virus, as revealed by the repression in syncytia formation upon curcumin treatment in SupT1 cells. Thus, non-toxic curcumin, which targets p300/CBP, may serve as a lead compound in combinatorial HIV therapeutics.

25 June 2022 in Journal of Autoimmunity
Verified
Journal Article
Closed access
NKNarendra Kumar
Narendra Kumar
AAArpan Acharya
Arpan Acharya
HGHoward E. Gendelman
Howard E. Gendelman
SBSiddappa Byrareddy
Siddappa Byrareddy

21 July 2020 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
SSSravani Singu
Sravani Singu
AAArpan Acharya
Arpan Acharya
KCKishore Challagundla
Kishore Challagundla
SBSiddappa Byrareddy
Siddappa Byrareddy
A novel coronavirus (2019-nCoV) caused a global pandemic in the months following the first four cases reported in Wuhan, China, on December 29, 2019. The elderly, immunocompromised, and those with preexisting conditions—such as asthma, cardiovascular disease (CVD), hypertension, chronic kidney disease (CKD), or obesity—experience higher risk of becoming severely ill if infected with the virus. Systemic social inequality and discrepancies in socioeconomic status (SES) contribute to higher incidence of asthma, CVD, hypertension, CKD, and obesity in segments of the general population. Such preexisting conditions bring heightened risk of complications for individuals who contract the coronavirus disease (COVID-19) from the virus (2019-nCoV)—also known as “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). In order to help vulnerable groups during times of a health emergency, focus must be placed at the root of the problem. Studying the social determinants of health (SDOH), and how they impact disadvantaged populations during times of crisis, will help governments to better manage health emergencies so that every individual has equal opportunity to staying healthy. This review summarizes the impact of social determinants of health (SDOH) during the COVID-19 pandemic.

1 November 2021 in Journal of Autoimmunity
Verified
Journal Article
Closed access
SKSaathvik R. Kannan
Saathvik R. Kannan
ASAustin N. Spratt
Austin N. Spratt
ACAlisha R. Cohen
Alisha R. Cohen
SNS. Hasan Naqvi
S. Hasan Naqvi
HCHitendr Chand
Hitendr Chand
Kamlendra SinghKamlendra Singh
Kamlendra Singh

13 December 2021 in Journal of Autoimmunity
Verified
Journal Article
Closed access
SKSaathvik R. Kannan
Saathvik R. Kannan
ASAustin N. Spratt
Austin N. Spratt
KSKalicharan Sharma
Kalicharan Sharma
HCHitendra S. Chand
Hitendra S. Chand
SBSiddappa Byrareddy
Siddappa Byrareddy
Kamlendra SinghKamlendra Singh
Kamlendra Singh